The Latest Analyst Ratings for BridgeBio Pharma
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for BridgeBio Pharma (NASDAQ:BBIO) in the last quarter. In the last 3 months, 4 analysts have offered 12-month price targets for BridgeBio Pharma with an average price target of $52.0, an increase of 13.04% from the previous average price target of $46.00.
October 24, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma has received bullish ratings from analysts, with an increased average price target. This could potentially lead to a positive impact on the stock price.
Analysts' ratings are a significant factor influencing stock prices. The bullish ratings and increased price target for BridgeBio Pharma indicate a positive sentiment towards the company, which could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100